Viewing nowRibavirin Capsule 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Korea B.M.I. Co., Ltd.

MFDS item code 201109261 · Approved 2011.10.27 · Insurance code 654802030
Treatment of neuropathic pain, treatment of fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy
This medication is used to treat peripheral and central neuropathic pain in adults. It is also utilized as an adjunct for partial seizures in epilepsy patients, effective in cases with or without secondary general symptoms. Additionally, it is used to treat chronic pain conditions known as fibromyalgia. It aids in alleviating pain and symptoms from various neurological disorders, thereby improving the quality of life for patients.
This medication is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Because this medication is eliminated primarily by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment.”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See “4. Discontinuation of Treatment.”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted with a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over a period of at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is excreted primarily by the kidneys as unchanged drug. Because the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For females, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25-100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the method of administration. b: A supplemental dose refers to an additional dose administered once. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors, requiring careful monitoring for symptoms of depression, mood changes, or unusual behavior during treatment. It should not be administered to patients with hypersensitivity to its ingredients or certain genetic lactose metabolism disorders. Diabetic patients may need to adjust the dosage of blood sugar control medications due to weight gain, and should discontinue the medication immediately if symptoms of angioedema occur. Elderly patients require caution due to an increased risk of falls from dizziness and drowsiness, and should consult a healthcare professional if they experience blurred vision or changes in eyesight. Abrupt discontinuation of this medication can lead to withdrawal symptoms such as insomnia, headaches, nausea, and anxiety; therefore, adjustments should be made under a doctor's instructions. Patients with a history of drug abuse require careful administration due to the potential for misuse or dependence on this medication, with close monitoring for signs of drug abuse. Patients with impaired renal function may require dosage adjustments. This medication should be used cautiously in patients with cardiovascular disease, especially those with congestive heart failure. When used in combination with other medications that have central nervous system depressant effects, especially opioids, the risk of respiratory depression is increased. Pregnant women should avoid taking this medication during early pregnancy due to the potential risk of fetal malformations, and women of childbearing age should use effective contraceptive methods. Breastfeeding women should carefully decide on breastfeeding as this medication can be transmitted through breast milk. Dizziness or drowsiness may occur during treatment, so driving or operating dangerous machinery should be avoided until symptoms improve. In case of overdose, severe drowsiness, confusion, or depression may occur, and treatment such as hemodialysis may be required. This medication should be kept out of the reach of children, and transferring it to another container may present a risk of quality degradation or accidents.
Suicidal thoughts, suicidal behavior, depression, abnormal mood and behavior changes, angioedema, facial swelling, periorbital swelling, upper respiratory tract swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, thoughts of suicide, pain, seizures, hyperhidrosis, misuse, abuse, dependence, hypoglycemia, increased appetite, loss of appetite, confusion, spatial disorientation, irritability, euphoria, decreased libido, depersonalization, paraphilia, restlessness, anxiety, mood fluctuations, emotional lability, emotional lows, emotional highs, difficulty finding appropriate terminology, hallucinations, abnormal dreams, increased libido, panic attacks, impulsivity, apathy, ataxia, abnormal motor coordination, equilibrium disorders, amnesia, attention impairment, memory impairment, tremors, dysarthria, sensory abnormalities, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, speech disorders, myoclonus, reflex reduction, movement disorders, psychomotor agitation, positional dizziness, hypersensitivity, burning sensation, active tremors, syncope, confusion, hypokinesia, olfactory disturbances, loss of taste, writing difficulties, diplopia, vertigo, auditory hypersensitivity, first-degree heart block, tachycardia, bradycardia, tachyarrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, hypersalivation, gastroesophageal reflux disease, oral sensory impairment, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urinary disorders, urinary incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, nipple discharge, breast enlargement, peripheral edema, edema, gait abnormalities, falls, feeling intoxicated, abnormal sensations, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, elevated serum creatine phosphokinase, increased aspartate aminotransferase, elevated blood sugar, decreased platelet count, reduced serum potassium, weight loss, elevated serum creatinine, reduced white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, congestive heart failure, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), affective disorders, drowsiness, confusion state, agitation, restlessness, seizures, shock, anaphylaxis-like symptoms, mucocutaneous syndrome, erythema multiforme
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. The storage temperature should be maintained between 15 degrees Celsius and 30 degrees Celsius to preserve its effectiveness and safety over time.
A hard capsule with an upper reddish-brown and a lower white color, containing white powder that is white or light yellow.
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Korea B.M.I. Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.